AlphAIalphai — Financial news for AI agents
prnewswire.comMAY 281 min read$INO

INOVIO to Participate in Upcoming Scientific and Investor Conferences

INOVIO (NASDAQ: INO) said it will participate in upcoming conferences. The company plans a June 4 fireside chat at the Jefferies Global Healthcare Conference in New York, and a June 11 poster presentation at the World Orphan Drug Congress in Boston on next-gen DNA medicine for rare disease protein replacement therapeutics. INOVIO management will also hold one-on-one investor meetings; a 90-day event replay will be available.

Original reporting
prnewswire.com
Published May 28, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 28, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
INOVIO to Participate in Upcoming Scientific and Investor Conferences — source image
Source · prnewswire.com
Decision brief

The 30-second read

$INONeutralLow
01

Why it matters

The only actionable element is the timing of management visibility and a poster presentation, which can affect short-term attention but not fundamentals absent new data.

02

Market read

This is primarily an investor-relations calendar update with no new trial results or guidance.

03

What to watch

Traders may instead wait for the actual poster details, webcast Q&A, or any subsequent press release that includes new efficacy/safety data.

Relevance 5/10Novelty 3/10Timing: Ahead of June 4 fireside chat and June 11 poster presentation.

Background

INOVIO is a biotech focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases; this release lists upcoming investor/scientific events.

Company-level read

Ticker impact

$INONeutralMedium confidence
Context

INOVIO (INO) announces participation in upcoming healthcare/investor conferences, including a scheduled June 11 poster presentation.

Expected impact

Likely low near-term impact; any move would be sentiment/attention-driven rather than fundamentals.

Evidence & confidence

The article is an event calendar update (fireside chat and poster) without results, guidance, or trial readouts.

Market effects

Sector

Biotech conference participation may modestly support broader DNA medicine/HPV-related sentiment, but no direct read-across catalyst is provided.

Regional

Minimal; events are investor-facing and not tied to regional economic or regulatory actions.

Global

Limited; no international regulatory filings, trial sites, or global partnership updates are mentioned.

Counterpoint

What could challenge this read

The market may discount conference attendance if prior posters/chat content has not translated into measurable clinical or commercial milestones.

Key entities

  • company
    INOVIO

    Company announcing upcoming scientific and investor conferences and a poster presentation schedule.

  • event
    Jefferies Global Healthcare Conference

    June 4 fireside chat in New York featuring INOVIO management.

  • event
    World Orphan Drug Congress

    June 11 poster presentation slot for INOVIO.

Read at source← All news

Related articles

AUG 14
$INOMedAI 8/10

Inovio (INO) Q2 2026 Earnings Call Transcript

Inovio (INO) discussed its Q2 2026 earnings call, focusing on FDA progress for its BLA for INO-3110 for recurrent respiratory papillomatosis. The FDA completed late-cycle review and prelicensure inspections, and Inovio expects the Oct. 30 PDUFA date. The company reported $18.3M net proceeds from a late-July equity offering and expects cash into late Q1 2027.

yahoo.com7 min
AUG 14
$INOMed

Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Inovio Pharmaceuticals said the FDA completed all scheduled pre-licensure inspections, with one observation addressed. Management reiterated that INO-3107 meets accelerated approval criteria and expects label negotiations in Sept 2026 ahead of an Oct 30 PDUFA. Cash runway extends into late Q1 2027 after a July 2026 $18.3M equity offering; Q3 2026 net cash burn is $18M.

yahoo.com6 min
AUG 12
$INOMed

INOVIO PHARMACEUTICALS, INC. (INO): Results of Operations and Financial Condition

INOVIO PHARMACEUTICALS, INC. (INO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights • U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a tar

SEC EDGAR 8-K5 min
JUL 30
$INOMedAI 8/10

INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Pharmaceuticals (Nasdaq: INO) priced an underwritten public offering of 21,052,632 shares plus warrants to buy up to 42,105,264 shares, or pre-funded warrants, at a combined price of $0.95 per share and $1.10 warrant exercise price. Gross proceeds are about $20.0 million, excluding option/warrant exercise. Closing expected around July 31, 2026.

prnewswire.com2 min